Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

@inproceedings{Redic2016ClinicalDI,
  title={Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor},
  author={Kimberly A. Redic and Shannon M. Hough and Erika M Price},
  booktitle={OncoTargets and therapy},
  year={2016}
}
BACKGROUND Panobinostat is a new agent for the treatment of relapsed and refractory multiple myeloma (rrMM) as part of a combination regimen. This article presents an overview of the mechanism of action, pharmacokinetics, safety, efficacy, patient care strategies, and role of the agent in treating rrMM patients. RESULTS Panobinostat belongs to the class of drugs known as histone deacetylase inhibitors, and has high activity against Class I, II, and IV nonhistone deacetylases and histone… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 43 references

A phase I study of ixazomib in combination with panobinostat and dexamethasone in patients with relapsed or refractory multiple myeloma

  • FJ Reu, J Valent, E Malek
  • Poster 4221,
  • 2015

A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM): comparison of two expansion cohorts

  • JG Berdeja, TB Gregory, EA Faber
  • Poster 1825,
  • 2015

A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma

  • A Chari, HJ Cho, S Len
  • Poster 4226,
  • 2015

Similar Papers

Loading similar papers…